CN110178792A - 一种动脉粥样硬化易损斑块小鼠模型的构建方法 - Google Patents
一种动脉粥样硬化易损斑块小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN110178792A CN110178792A CN201910375476.6A CN201910375476A CN110178792A CN 110178792 A CN110178792 A CN 110178792A CN 201910375476 A CN201910375476 A CN 201910375476A CN 110178792 A CN110178792 A CN 110178792A
- Authority
- CN
- China
- Prior art keywords
- ldlr
- fbn1
- mouse
- vulnerable plaque
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 28
- 238000010172 mouse model Methods 0.000 title claims abstract description 19
- 238000010276 construction Methods 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 16
- 101100119832 Mus musculus Fbn1 gene Proteins 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims abstract description 13
- 238000011160 research Methods 0.000 claims abstract description 13
- 108010030229 Fibrillin-1 Proteins 0.000 claims abstract description 12
- 102000005867 Fibrillin-1 Human genes 0.000 claims abstract description 12
- 230000002068 genetic effect Effects 0.000 claims abstract description 7
- 238000009396 hybridization Methods 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 3
- 210000001367 artery Anatomy 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 210000004969 inflammatory cell Anatomy 0.000 abstract description 7
- 238000011813 knockout mouse model Methods 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 208000032843 Hemorrhage Diseases 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 27
- 235000009200 high fat diet Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000003209 gene knockout Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 3
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000035778 pathophysiological process Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 210000003291 sinus of valsalva Anatomy 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150013552 LDLR gene Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910375476.6A CN110178792B (zh) | 2019-05-07 | 2019-05-07 | 一种动脉粥样硬化易损斑块小鼠模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910375476.6A CN110178792B (zh) | 2019-05-07 | 2019-05-07 | 一种动脉粥样硬化易损斑块小鼠模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110178792A true CN110178792A (zh) | 2019-08-30 |
CN110178792B CN110178792B (zh) | 2021-11-16 |
Family
ID=67715760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910375476.6A Active CN110178792B (zh) | 2019-05-07 | 2019-05-07 | 一种动脉粥样硬化易损斑块小鼠模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110178792B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111607597A (zh) * | 2020-06-02 | 2020-09-01 | 成都中科奥格生物科技有限公司 | Asgr1突变基因在制备拟人化的低血脂代谢动物模型中的应用 |
CN113925022A (zh) * | 2021-10-22 | 2022-01-14 | 莫汉有 | 一种系统性红斑狼疮并动脉粥样硬化动物模型构建方法 |
CN114557318A (zh) * | 2022-03-28 | 2022-05-31 | 中山大学 | 一种基于pedf/ldlr双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 |
CN117165631A (zh) * | 2023-11-01 | 2023-12-05 | 潍坊医学院 | 一种动脉粥样硬化斑块快速造模基因小鼠的构建方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863548A (zh) * | 2003-07-01 | 2006-11-15 | 迪亚-B技术有限公司 | 治疗细胞外基质紊乱的方法和组合物 |
US20070253901A1 (en) * | 2006-04-27 | 2007-11-01 | David Deng | Atherosclerosis genes and related reagents and methods of use thereof |
EP2669381A1 (en) * | 2012-05-30 | 2013-12-04 | AmVac AG | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein |
EP2738263A1 (en) * | 2012-11-30 | 2014-06-04 | Fundacion para la Investigacion del Hospital Clinico de la Comunidad Valenciana | Methods for DNA rearrengements analysis |
CN103889433A (zh) * | 2011-08-10 | 2014-06-25 | 德普伊新特斯产品有限责任公司 | 使用脐带组织来源的细胞治疗外周血管疾病 |
CN106244557A (zh) * | 2016-08-29 | 2016-12-21 | 中国农业科学院北京畜牧兽医研究所 | 定点突变ApoE基因与LDLR基因的方法 |
CN108085384A (zh) * | 2018-02-09 | 2018-05-29 | 国家卫生计生委科学技术研究所 | 遗传性心血管疾病检测方法 |
CN109364248A (zh) * | 2018-10-16 | 2019-02-22 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
-
2019
- 2019-05-07 CN CN201910375476.6A patent/CN110178792B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863548A (zh) * | 2003-07-01 | 2006-11-15 | 迪亚-B技术有限公司 | 治疗细胞外基质紊乱的方法和组合物 |
US20070253901A1 (en) * | 2006-04-27 | 2007-11-01 | David Deng | Atherosclerosis genes and related reagents and methods of use thereof |
CN103889433A (zh) * | 2011-08-10 | 2014-06-25 | 德普伊新特斯产品有限责任公司 | 使用脐带组织来源的细胞治疗外周血管疾病 |
EP2669381A1 (en) * | 2012-05-30 | 2013-12-04 | AmVac AG | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein |
EP2738263A1 (en) * | 2012-11-30 | 2014-06-04 | Fundacion para la Investigacion del Hospital Clinico de la Comunidad Valenciana | Methods for DNA rearrengements analysis |
CN106244557A (zh) * | 2016-08-29 | 2016-12-21 | 中国农业科学院北京畜牧兽医研究所 | 定点突变ApoE基因与LDLR基因的方法 |
CN108085384A (zh) * | 2018-02-09 | 2018-05-29 | 国家卫生计生委科学技术研究所 | 遗传性心血管疾病检测方法 |
CN109364248A (zh) * | 2018-10-16 | 2019-02-22 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
Non-Patent Citations (5)
Title |
---|
AMMAR KURDI等: "Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis", 《VASCULAR PHARMACOLOGY》 * |
VESELI等: "Animal models of atherosclerosis", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
李华等: "奥美沙坦酯对载脂蛋白E基因敲除小鼠动脉粥样硬化的影响", 《中华医学杂志》 * |
樊好飞 等: ""基因敲除动脉粥样硬化小鼠模型研究进展"", 《中药药理学与毒理学杂志》 * |
陈文强等: "动脉粥样硬化易损斑块的动物模型和检测技术", 《中国动脉硬化杂志》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111607597A (zh) * | 2020-06-02 | 2020-09-01 | 成都中科奥格生物科技有限公司 | Asgr1突变基因在制备拟人化的低血脂代谢动物模型中的应用 |
CN111607597B (zh) * | 2020-06-02 | 2023-08-08 | 成都中科奥格生物科技有限公司 | Asgr1突变基因在制备拟人化的低血脂代谢动物模型中的应用 |
CN113925022A (zh) * | 2021-10-22 | 2022-01-14 | 莫汉有 | 一种系统性红斑狼疮并动脉粥样硬化动物模型构建方法 |
CN114557318A (zh) * | 2022-03-28 | 2022-05-31 | 中山大学 | 一种基于pedf/ldlr双基因敲除的非酒精性脂肪性肝炎小鼠模型构建方法及应用 |
CN117165631A (zh) * | 2023-11-01 | 2023-12-05 | 潍坊医学院 | 一种动脉粥样硬化斑块快速造模基因小鼠的构建方法 |
CN117165631B (zh) * | 2023-11-01 | 2024-02-13 | 潍坊医学院 | 一种动脉粥样硬化斑块快速造模基因小鼠的构建方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110178792B (zh) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110178792A (zh) | 一种动脉粥样硬化易损斑块小鼠模型的构建方法 | |
CN106148416B (zh) | Cyp基因敲除大鼠的培育方法及其肝微粒体的制备方法 | |
CN108660161B (zh) | 基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法 | |
EP3381278B1 (en) | Method for preparing a canine model of atherosclerosis | |
Lai et al. | Diverse phenotypes and specific transcription patterns in twenty mouse lines with ablated LincRNAs | |
Han et al. | Generation of Hoxc13 knockout pigs recapitulates human ectodermal dysplasia–9 | |
Yang et al. | DNMT 1 maintains hypermethylation of CAG promoter specific region and prevents expression of exogenous gene in fat-1 transgenic sheep | |
US20210275599A1 (en) | Mitochondrial augmentation therapy of brain diseases | |
US20210252075A1 (en) | Mitochondrial augmentation therapy of liver diseases | |
CN109234278B (zh) | 构建ApoC2基因敲除仓鼠模型的试剂盒和方法 | |
Patrushev et al. | Mutations in mitochondrial DNA and approaches for their correction | |
Díez-del-Molino et al. | Genomics of adaptive evolution in the woolly mammoth | |
US20210290691A1 (en) | Mitochondrial augmentation therapy of muscle diseases | |
CN111607597B (zh) | Asgr1突变基因在制备拟人化的低血脂代谢动物模型中的应用 | |
CN111778278B (zh) | 一种Slfn4缺失的动脉粥样硬化模型小鼠的构建方法及其应用 | |
CN107447005A (zh) | p53基因突变与端粒功能异常的用途 | |
JP6172699B2 (ja) | 高脂血症モデルブタ | |
Hernández-Gutierrez et al. | NF-κB signaling blockade by Bay 11-7085 during early cardiac morphogenesis induces alterations of the outflow tract in chicken heart | |
WO2018196874A1 (zh) | 遗传工程化的非人类哺乳动物及其构建方法和应用 | |
CN116473020A (zh) | 一种Macrosialin基因缺失动脉粥样硬化小鼠模型的构建方法及其应用 | |
CN111705063B (zh) | Asgr1突变基因及其在制备哺乳动物肝损伤敏感模型中的应用 | |
Shen et al. | Tissue specific expression of angiotensin converting enzyme: a new way to study an old friend | |
CN111647628B (zh) | Ces2基因敲除大鼠模型及其构建方法和应用 | |
CN109456996B (zh) | 构建abca1基因敲除仓鼠模型的试剂盒和方法 | |
CN117165631B (zh) | 一种动脉粥样硬化斑块快速造模基因小鼠的构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Yu Bo Inventor after: Tian Jinwei Inventor after: Guo Shouli Inventor after: Wang Xueyu Inventor after: Tian Jiangtian Inventor after: Fu Yahong Inventor before: Yu Bo Inventor before: Tian Jinwei Inventor before: Wang Xueyu Inventor before: Guo Shouli Inventor before: Tian Jiangtian Inventor before: Fu Yahong |
|
GR01 | Patent grant | ||
GR01 | Patent grant |